Skybiotech Healthcare Ltd. Reports Narrowed FY26 Net Loss

Skybiotech Healthcare Ltd. reported a consolidated net loss of ₹1.12 crore for the fiscal year ended March 31, 2026. The company's revenue from operations stood at ₹7.10 crore.

Reader Takeaway: Loss reduction a positive, but sustained revenue growth and positive cash flow are key challenges ahead.

What just happened

Skybiotech Healthcare Limited (formerly Kapil Cotex Limited) announced its audited consolidated financial results for FY26. The company posted a net loss of ₹1.12 crore (₹111.68 lakh) on revenues of ₹7.10 crore (₹709.78 lakh). This marks a reduction in net losses compared to the previous fiscal year's loss of ₹2.37 crore (₹236.89 lakh).

Why this matters

For investors, the narrowed loss indicates some operational improvement, but the company remains unprofitable. The significant difference between standalone revenue (₹0.067 crore) and consolidated revenue (₹7.10 crore) highlights the heavy reliance on its subsidiary, Skybiotech Life Sciences Private Limited, for business operations.

The backstory

In November 2025, the company officially changed its name from Kapil Cotex Limited to Skybiotech Healthcare Limited, signaling a strategic shift in its business focus towards the healthcare sector. The company operates as a single reporting unit without distinct business segments.

What changes now

Investors will be closely watching the company's ability to leverage its subsidiary's operations to achieve profitability and positive cash flow. The name change and strategic pivot suggest a renewed focus on growth within the healthcare and biotech space.

Risks to watch

Continued negative cash flow from operating activities is a significant concern, indicating the business is still burning cash. Achieving profitability and sustainable revenue growth remain key challenges.

Peer comparison

As Skybiotech Healthcare operates in the healthcare and potentially biotech sectors, its performance could be benchmarked against other small-cap companies in these segments focused on R&D and market penetration. However, specific peer data was not provided in the filing.

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹7.10 crore
• Consolidated Revenue FY25: ₹7.05 crore (largely flat)
• Consolidated Net Loss FY26: ₹1.12 crore
• Consolidated Net Loss FY25: ₹2.37 crore (narrowed)

What to track next

Investors should monitor future quarterly results for signs of revenue growth, improvements in cash flow generation, and progress towards overall profitability following the strategic name change and focus on the healthcare sector.